National DNA Day
National DNA Day commemorates the successful completion of the Human Genome Project in 2003 and the discovery of DNA’s double helix in 1953.
Related Articles
MIG6 mediates adaptive and acquired resistance to ALK/ROS1 fusion kinase inhibition through EGFR bypass signaling – PubMed
Despite the initial benefit from tyrosine kinase inhibitors (TKIs) targeting oncogenic ALK and ROS1 gene fusions in non-small cell lung cancer, complete responses are rare…
MIG6 mediates adaptive and acquired resistance to ALK/ROS1 fusion kinase inhibition through EGFR bypass signaling – PubMed
Despite the initial benefit from tyrosine kinase inhibitors (TKIs) targeting oncogenic ALK and ROS1 gene fusions in non-small cell lung cancer, complete responses are rare…
MIG6 mediates adaptive and acquired resistance to ALK/ROS1 fusion kinase inhibition through EGFR bypass signaling – PubMed
Despite the initial benefit from tyrosine kinase inhibitors (TKIs) targeting oncogenic ALK and ROS1 gene fusions in non-small cell lung cancer, complete responses are rare…
JCI Insight – MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF
ResearchIn-Press PreviewOncology Open Access | 10.1172/jci.insight.173688 Takahiro Utsumi,1 Yuki Shimizu,1 Ai Takemoto,1 Tomoko Oh-hara,1 Ken Uchibori,2 Sophia Subat-Motoshi,3 Hironori Ninomiya,3 Kengo Takeuchi,4 Makoto Nishio,2 Yasunari…
Time to shift the burden of proof for oncogene-positive cancer? – Nature Reviews Clinical Oncology
Rearrangements of the ALK gene have been associated with sensitivity to crizotinib and other kinase inhibitors with activity against ALK. The phase III PROFILE 1007…
MIG6 mediates adaptive and acquired resistance to ALK/ROS1 fusion kinase inhibition through EGFR bypass signaling
Abstract. Despite the initial benefit from tyrosine kinase inhibitors (TKIs) targeting oncogenic ALK and ROS1 gene fusions in non-small cell lung cancer, complete responses are…
A Functional sgRNA-CRISPR screening method for generating murine RET and NTRK1 rearranged oncogenes – PubMed
CRISPR/Cas9 gene editing represents a powerful tool for investigating fusion oncogenes in cancer biology. Successful experiments require that sgRNAs correctly associate with their target sequence…
Scientists release a new human “pangenome” reference
Researchers have released a new high-quality collection of reference human genome sequences that captures substantially more diversity from different human populations than what was previously…
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types
PurposeGene fusions involving receptor tyrosine kinases (RTKs) define an important class of genomic alterations with many successful targeted therapies now approved for ALK, ROS1, RET…